Antibiotic therapy for fever with low white blood cells in blood cancer
Part of Blood & lymphatic clinical trials.
This trial tests whether an antibiotic called ceftazidime-avibactam (CAZ-AVI) can help patients with blood cancers who have a fever and very low infection-fighting white blood cells. It may be an option for people whose doctors plan to use this specific antibiotic to treat their fever.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a blood cancer like leukemia, lymphoma, multiple myeloma, or severe aplastic anemia.
- Your infection-fighting white cells (neutrophils) must be very low at the start of the study or expected to drop soon.
- You must have a fever (temperature at least 100.9°F by mouth, or 100.4°F under the arm for over an hour).
- You must be able to take care of yourself (ECOG score 0-2).
- Your doctor must be planning to treat your fever with a specific antibiotic called ceftazidime-avibactam.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether proteins in your blood can predict complications when you have a fever and very low white blood cells after cancer treatment. It aims to help doctors choose the best antibiotics early on.
This trial tests whether it is safe to stop antibiotics earlier than usual in patients with a low white blood cell count (neutropenia) who have had a fever but have been fever-free for 48 hours. The goal is to reduce unnecessary antibiotic use and its side effects.
This trial looks at whether adding a medicine called G-CSF (which helps the body make more white blood cells) to antibiotics is better than antibiotics alone for children with cancer who develop a fever and low blood cell counts after chemotherapy.
This trial tests whether a newer antibiotic (ceftolozane/tazobactam) works as well as the standard drug (meropenem) for treating fever and low white blood cell counts in people who carry or are at risk for a certain type of resistant bacteria (ESBL). If you are colonized with ESBL or have recently used certain antibiotics, you may be eligible.
This trial compares two antibiotics, ciprofloxacin and ceftazidime, to see which works better for treating fever in children with blood cancer who have a high risk of infection due to low white blood cells. The goal is to find the best treatment to help your child recover faster.
This study looks at how a certain antibiotic (ceftazidime-avibactam) works in people with blood cancers or stem cell transplants, and how the drug levels affect the bacteria. It aims to find the best dosing to fight infections and reduce resistance.
Hear when a new Febrile Neutropenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.